Aditya Juloori, MD
Radiation Oncology · Chicago, ILNPI 1952714636
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $57,830 of the $73,097 with a category attached, or 79.1%. 15 manufacturers reported payments, led by AstraZeneca at 43.8% of the total. 2025 is the largest year on record at $38,669, more than ten times the $1,224 reported in 2021. Among radiation oncology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 96 payments — averaging $761.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$32K
- Merck$14K
- Daiichi Sankyo Inc.$11K
- EMD Serono, Inc.$8K
- GE HealthCare$4K
- Siemens Medical Solutions USA, Inc.$2K
- plus $3K from 9 others
Across 4 payments — averaging $38,178 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$104K
- Merck$41K
- Organon$7K
What the payments were for
- Consulting fees$57,83079%
- Speaking & faculty fees$4,9787%
- Travel & lodging$7,91911%
- Food & beverage$2,3703%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $31,982 |
| Merck | 20 | $13,744 |
| Daiichi Sankyo Inc. | 9 | $10,698 |
| EMD Serono, Inc. | 2 | $7,987 |
| GE HealthCare | 2 | $3,924 |
| Siemens Medical Solutions USA, Inc. | 10 | $1,848 |
| Isoray, Inc | 3 | $1,072 |
| Regeneron | 2 | $824 |
| Lantheus Medical Imaging, Inc. | 1 | $500 |
| Taiho Oncology, Inc. | 5 | $192 |
| IBA Proton Therapy, Inc. | 1 | $134 |
| Tactile Systems Technology Inc | 3 | $72 |
| Novartis | 3 | $63 |
| Medtronic | 1 | $39 |
| Novocure Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$73,097 in reported general payments places this provider in the 95th percentile of 242 radiation oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 18 | $192 |
| Famotidine | 23 | $77 |
| Memantine Hcl | 11 | $35 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Chicago
- Sean PitrodaChicago$103K
- Steven ChmuraChicago$59K
- William SmallChicago$54K
- Ken TatebeChicago$42K
- Sean SachdevChicago$34K
- Yasmin HasanChicago$18K
- Ralph WeichselbaumChicago$11K
- Tarita ThomasChicago$8K
- Gaurav MarwahaChicago$6K
- Dian WangChicago$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.